Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors

The aim of this study was to characterize the treatment response and serious adverse events of ledipasvir plus sofosbuvir therapies in Japanese patients infected with hepatitis C virus (HCV) genotype 1 (GT1). This retrospective study analyzed 240 Japanese HCV GT1 patients treated for 12 weeks with 9...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanda, Tatsuo, Yasui, Shin, Nakamura, Masato, Suzuki, Eiichiro, Arai, Makoto, Ooka, Yoshihiko, Ogasawara, Sadahisa, Chiba, Tetsuhiro, Saito, Tomoko, Haga, Yuki, Takahashi, Koji, Sasaki, Reina, Wu, Shuang, Nakamoto, Shingo, Tawada, Akinobu, Maruyama, Hitoshi, Imazeki, Fumio, Kato, Naoya, Yokosuka, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454819/
https://www.ncbi.nlm.nih.gov/pubmed/28441362
http://dx.doi.org/10.3390/ijms18050906

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454819/
https://www.ncbi.nlm.nih.gov/pubmed/28441362
http://dx.doi.org/10.3390/ijms18050906

Ejemplares similares